Gender differences in mediators of left ventricular hypertrophy in dialysis patients

T Savage1, M Giles, C V Tomson

  • 1Anthony Raine Laboratories, Bristol, UK.

Clinical Nephrology
|April 3, 1998
PubMed

Insights

Left ventricular hypertrophy (LVH) is common in dialysis patients and affects both sexes equally. However, pulse pressure is a key driver in men, while other factors influence LVH in women.

Area of Science:

  • Nephrology
  • Cardiology
  • Hypertension

Background:

  • Left ventricular hypertrophy (LVH) is a significant predictor of cardiovascular mortality in dialysis patients.
  • Risk factors for LVH differ between genders in the general population.

Purpose of the Study:

  • To investigate the prevalence and determinants of LVH in dialysis patients.
  • To explore potential gender-specific differences in LVH development.

Main Methods:

  • Studied 46 non-diabetic dialysis patients (hemodialysis and CAPD).
  • Assessed 48-hour ambulatory blood pressure (BP), left ventricular mass index (LVMI) via echocardiography, and blood markers (hemoglobin, PTH, urea, electrolytes).

Main Results:

  • LVH was prevalent in 72% of men and 68% of women.
  • LVMI correlated with 48-hour pulse pressure, systolic BP, PTH, serum calcium, and hemoglobin.
  • Multiple regression identified pulse pressure and systolic BP as significant predictors of LVMI.
  • In men, pulse pressure strongly predicted LVMI, especially at night; no significant predictors were found in women.

Conclusions:

  • LVH is equally prevalent in male and female dialysis patients.
  • Determinants of LVH differ by gender, with pulse pressure being crucial in males.
  • Unidentified factors likely play a predominant role in LVH development in female dialysis patients.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...